Topic Hub

Epitalon — Regulatory History

4 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.

4articles

26keywords mapped

2025-01-28latest review

Explore

Epitalon — Regulatory History library

Showing 4 of 4 clinical reviews.

Safety2025-01-28

Epitalon FAERS Safety Signals: What the FDA Adverse Event Data Actually Shows

A clinician-focused review of Epitalon FAERS safety signals, FDA regulatory status, absence of approved labeling, and what post-market surveillance data does and does not tell us about this unscheduled tetrapeptide.

Read clinical review

Clinical Reviews2026-05-25

Epitalon Global Regulatory Status: FDA, EMA, and International Classification

Epitalon (Ala-Glu-Asp-Gly) has no FDA or EMA approval. Learn the current regulatory classification in the US, EU, Russia, Australia, and other markets, plus what the science actually shows.

Read clinical review

Questions2026-05-25

Epitalon Legal and Patent Challenges: FDA Status, Regulatory Barriers, and What Clinicians Should Know

Epitalon (epithalon) has no FDA approval, no active U.S. patent protection, and no completed phase III trials. This article covers the peptide's regulatory status, legal gray areas, and what the clinical evidence actually supports.

Read clinical review

Safety2026-05-26

Epitalon Pipeline and Next-Gen Research: FDA Status, Safety Data, and What Comes After the Tetrapeptide

Epitalon has no FDA approval and remains a research-only peptide. This article covers its regulatory status, published safety signals, clinical trial gaps, and the next-generation telomerase-targeting compounds in early development.

Read clinical review